The benefit of complete revascularization after primary PCI for STEMI is attenuated by increasing age: Results from the DANAMI‐3‐PRIMULTI randomized study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The benefit of complete revascularization after primary PCI for STEMI is attenuated by increasing age : Results from the DANAMI‐3‐PRIMULTI randomized study. / Joshi, Francis R.; Lønborg, Jacob; Sadjadieh, Golnaz; Helqvist, Steffen; Holmvang, Lene; Sørensen, Rikke; Jørgensen, Erik; Pedersen, Frants; Tilsted, Hans Henrik; Høfsten, Dan; Køber, Lars; Kelbæk, Henning; Engstrøm, Thomas.
I: Catheterization and Cardiovascular Interventions, Bind 97, Nr. 4, 2021, s. E467–E474.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The benefit of complete revascularization after primary PCI for STEMI is attenuated by increasing age
T2 - Results from the DANAMI‐3‐PRIMULTI randomized study
AU - Joshi, Francis R.
AU - Lønborg, Jacob
AU - Sadjadieh, Golnaz
AU - Helqvist, Steffen
AU - Holmvang, Lene
AU - Sørensen, Rikke
AU - Jørgensen, Erik
AU - Pedersen, Frants
AU - Tilsted, Hans Henrik
AU - Høfsten, Dan
AU - Køber, Lars
AU - Kelbæk, Henning
AU - Engstrøm, Thomas
PY - 2021
Y1 - 2021
N2 - ObjectivesTo ascertain the effect of age on outcomes after culprit-only and complete revascularization after Primary PCI (PPCI) for ST-elevation myocardial infarction (STEMI).BackgroundThe numbers of older patients being treated with PPCI are increasing. The optimal management of nonculprit stenoses in such patients is unclear.MethodsWe conducted an analysis of patients aged ≥75 years randomized in the DANAMI-3-PRIMULTI study to either culprit-only or complete FFR-guided revascularization. The primary endpoint was a composite of all-cause mortality, nonfatal reinfarction, and ischaemia-driven revascularization of lesions in noninfarct-related arteries after a median of 27 months of follow-up.ResultsOne hundred and ten of six hundred and twenty seven patients in the DANAMI-3-PRIMULTI trial were aged ≥75 years. These patients were more likely female (p < .001), hypertensive (p < .001), had lower hemoglobin levels (p < .001), and higher serum creatinine levels (p < .001) than the younger patients in the trial. Other than less use of drug-eluting stents (96.6 versus 88.0%: p = .02), there were no significant differences in procedural technique and success between patients aged <75 years and those ≥75 years of age. There was no significant difference in the incidence of the primary endpoint in patients ≥75 years randomized to culprit-only or FFR-guided complete revascularization (HR 1.49 [95% CI 0.57–4.65]; log-rank p = .19; p for interaction versus patients <75 years <.001). There was a significant interaction between age as a continuous variable, treatment assignment, and the primary outcome (p < .001); beyond the age of about 75 years, there may be no prognostic advantage to complete revascularization.ConclusionsIn patients ≥75 years, after treatment of the culprit lesion in STEMI, there is no significant prognostic benefit to prophylactic complete revascularization of nonculprit stenoses. Pending further study, data would support a symptom-guided approach to further invasive treatment.
AB - ObjectivesTo ascertain the effect of age on outcomes after culprit-only and complete revascularization after Primary PCI (PPCI) for ST-elevation myocardial infarction (STEMI).BackgroundThe numbers of older patients being treated with PPCI are increasing. The optimal management of nonculprit stenoses in such patients is unclear.MethodsWe conducted an analysis of patients aged ≥75 years randomized in the DANAMI-3-PRIMULTI study to either culprit-only or complete FFR-guided revascularization. The primary endpoint was a composite of all-cause mortality, nonfatal reinfarction, and ischaemia-driven revascularization of lesions in noninfarct-related arteries after a median of 27 months of follow-up.ResultsOne hundred and ten of six hundred and twenty seven patients in the DANAMI-3-PRIMULTI trial were aged ≥75 years. These patients were more likely female (p < .001), hypertensive (p < .001), had lower hemoglobin levels (p < .001), and higher serum creatinine levels (p < .001) than the younger patients in the trial. Other than less use of drug-eluting stents (96.6 versus 88.0%: p = .02), there were no significant differences in procedural technique and success between patients aged <75 years and those ≥75 years of age. There was no significant difference in the incidence of the primary endpoint in patients ≥75 years randomized to culprit-only or FFR-guided complete revascularization (HR 1.49 [95% CI 0.57–4.65]; log-rank p = .19; p for interaction versus patients <75 years <.001). There was a significant interaction between age as a continuous variable, treatment assignment, and the primary outcome (p < .001); beyond the age of about 75 years, there may be no prognostic advantage to complete revascularization.ConclusionsIn patients ≥75 years, after treatment of the culprit lesion in STEMI, there is no significant prognostic benefit to prophylactic complete revascularization of nonculprit stenoses. Pending further study, data would support a symptom-guided approach to further invasive treatment.
U2 - 10.1002/ccd.29131
DO - 10.1002/ccd.29131
M3 - Journal article
C2 - 32681717
VL - 97
SP - E467–E474
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
SN - 1522-1946
IS - 4
ER -
ID: 284096897